Jonathan Lloyd Jones
Corporate Officer/Principal at The Food & Drug Law Institute
Profile
Jonathan B.
Lloyd Jones is a professional with current jobs at Biotechnology Innovation Organization, Institute of Chartered Accountants in England & Wales, and The Food & Drug Law Institute.
He has former jobs at Genzyme Corp., Catalent JNP, Inc., Ernst & Young LLP, Deloitte Touche Tohmatsu (Hong Kong), TetraLogic Pharmaceuticals Corp., TransMolecular, Inc., The Royal Bank of Scotland International Ltd., Seneca Biopharma, Inc., and Royal Bank of Scotland (Nassau) Ltd.
He received an undergraduate degree from the University of Bradford and an MBA from The Wharton School of the University of Pennsylvania.
Jonathan Lloyd Jones active positions
Companies | Position | Start |
---|---|---|
The Food & Drug Law Institute
The Food & Drug Law Institute Miscellaneous Commercial ServicesCommercial Services The Food & Drug Law Institute is a nonprofit membership organization that provides education, training, publications, and professional engagement opportunities in the field of food and drug law. The non-profit company is based in Washington. The American company offers a platform for stakeholders to inform innovative public policy, law, and regulation. Christine M. Simmon has been the CEO of the company since 2022. | Corporate Officer/Principal | 1999-12-31 |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Corporate Officer/Principal | 1999-12-31 |
Institute of Chartered Accountants in England & Wales
Institute of Chartered Accountants in England & Wales Miscellaneous Commercial ServicesCommercial Services The Institute of Chartered Accountants in England & Wales ensures that its members, students, and affiliates maintain the highest standards of professional competency and conduct to protect the public interest. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. With over 150,000 members, the institute provides technical information, helplines, and communities to its members. | Corporate Officer/Principal | - |
Former positions of Jonathan Lloyd Jones
Companies | Position | End |
---|---|---|
PALISADE BIO, INC. | Director of Finance/CFO | 2017-04-29 |
JUNIPER PHARMACEUTICALS INC | Director of Finance/CFO | 2014-09-30 |
TransMolecular, Inc.
TransMolecular, Inc. BiotechnologyHealth Technology TransMolecular is an oncology-focused biotechnology company committed to developing novel proprietary drugs to diagnose and treat human diseases using a novel tumor targeting platform called TM601. Their development program to date has explored the therapeutic use of TM601 in cancer and neovascular diseases of the eye, and their lead candidate, TM601 conjugated to the radioactive isotope 131I, has a Special Protocol Agreement (SPA) with the FDA for a pivotal, Phase 3 trial in newly diagnosed glioblastoma multiforme (glioma). TM601 has unique properties of highly specific tumor cell binding and internalization while not affecting normal cells, targeting both primary disease sites and metastases. The interaction of TM601 with a specific protein known to be over-expressed on the surface of tumor cells and vascular endothelium is implicated in these tumor-specific binding properties. Conjugated to an anti-cancer radioactive isotope, TM601 has been successful in human and animal models in demonstrating selective targeting and uptake in a number of different tumor types, and in tumor locations within the central nervous system (CNS) and peripherally. Expanded research confirms that TM601 can deliver a variety of conjugates, creating potential for development of a wide array of anti-cancer therapies. In addition to the tumor targeting capability of TM601, a number of studies have also revealed that TM0601 exerts robust anti-angiogenic effects on vessels associated with neovascular disease. Pursuing this anti-angiogenic potential further, They have also determined the utility of TM601 in animal ophthalmic models. The company is leveraging its platform in strategic collaborations with partners seeking to expand product pipelines, extend product life-cycles for existing anti-tumor compounds, or optimize therapeutic activity of marginally effective or restrictively toxic drugs. | Director of Finance/CFO | 2009-12-31 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 2005-12-31 |
Deloitte Touche Tohmatsu (Hong Kong)
Deloitte Touche Tohmatsu (Hong Kong) Miscellaneous Commercial ServicesCommercial Services Part of Deloitte LLP (New York), Deloitte Touche Tohmatsu (Hong Kong) is a Chinese company that provides accounting services. The company is based in Hong Kong, Hong Kong. | Comptroller/Controller/Auditor | 1985-12-31 |
Training of Jonathan Lloyd Jones
University of Bradford | Undergraduate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
TETRALOGIC PHARMACEUTICALS CORPORATION | Health Technology |
Private companies | 10 |
---|---|
Catalent JNP, Inc.
Catalent JNP, Inc. Pharmaceuticals: MajorHealth Technology Catalent JNP, Inc. engages in the research and development of drugs and therapeutics. It offers analytical characterization and pre-formulation testing; formulation development; and clinical manufacturing of capsules and tablets. The company was founded in December 1986 and is headquartered in Somerset, NJ. | Health Technology |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
TransMolecular, Inc.
TransMolecular, Inc. BiotechnologyHealth Technology TransMolecular is an oncology-focused biotechnology company committed to developing novel proprietary drugs to diagnose and treat human diseases using a novel tumor targeting platform called TM601. Their development program to date has explored the therapeutic use of TM601 in cancer and neovascular diseases of the eye, and their lead candidate, TM601 conjugated to the radioactive isotope 131I, has a Special Protocol Agreement (SPA) with the FDA for a pivotal, Phase 3 trial in newly diagnosed glioblastoma multiforme (glioma). TM601 has unique properties of highly specific tumor cell binding and internalization while not affecting normal cells, targeting both primary disease sites and metastases. The interaction of TM601 with a specific protein known to be over-expressed on the surface of tumor cells and vascular endothelium is implicated in these tumor-specific binding properties. Conjugated to an anti-cancer radioactive isotope, TM601 has been successful in human and animal models in demonstrating selective targeting and uptake in a number of different tumor types, and in tumor locations within the central nervous system (CNS) and peripherally. Expanded research confirms that TM601 can deliver a variety of conjugates, creating potential for development of a wide array of anti-cancer therapies. In addition to the tumor targeting capability of TM601, a number of studies have also revealed that TM0601 exerts robust anti-angiogenic effects on vessels associated with neovascular disease. Pursuing this anti-angiogenic potential further, They have also determined the utility of TM601 in animal ophthalmic models. The company is leveraging its platform in strategic collaborations with partners seeking to expand product pipelines, extend product life-cycles for existing anti-tumor compounds, or optimize therapeutic activity of marginally effective or restrictively toxic drugs. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
The Royal Bank of Scotland International Ltd.
The Royal Bank of Scotland International Ltd. Major BanksFinance The Royal Bank of Scotland International Ltd. provides personal and corporate banking services. It offers offshore banking, personal banking, and corporate banking. The company was founded in 1966 and is headquartered in St. Helier, Jersey. | Finance |
Deloitte Touche Tohmatsu (Hong Kong)
Deloitte Touche Tohmatsu (Hong Kong) Miscellaneous Commercial ServicesCommercial Services Part of Deloitte LLP (New York), Deloitte Touche Tohmatsu (Hong Kong) is a Chinese company that provides accounting services. The company is based in Hong Kong, Hong Kong. | Commercial Services |
The Food & Drug Law Institute
The Food & Drug Law Institute Miscellaneous Commercial ServicesCommercial Services The Food & Drug Law Institute is a nonprofit membership organization that provides education, training, publications, and professional engagement opportunities in the field of food and drug law. The non-profit company is based in Washington. The American company offers a platform for stakeholders to inform innovative public policy, law, and regulation. Christine M. Simmon has been the CEO of the company since 2022. | Commercial Services |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
Institute of Chartered Accountants in England & Wales
Institute of Chartered Accountants in England & Wales Miscellaneous Commercial ServicesCommercial Services The Institute of Chartered Accountants in England & Wales ensures that its members, students, and affiliates maintain the highest standards of professional competency and conduct to protect the public interest. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. With over 150,000 members, the institute provides technical information, helplines, and communities to its members. | Commercial Services |
Seneca Biopharma, Inc.
Seneca Biopharma, Inc. BiotechnologyHealth Technology Seneca Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. Its pipeline includes NSI-189 small molecule program, NSI-566 stem cell therapy program, and novel & proprietary chemical entity screening platform. The company was founded by I. Richard Garr, Karl Y. Johe, and Merrill Solomon in 1996 and is headquartered in Germantown, MD. | Health Technology |
- Stock Market
- Insiders
- Jonathan Lloyd Jones